- Conditions
- Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Stage IB Esophageal Cancer AJCC v7, Stage IIA Esophageal Cancer AJCC v7, Stage IIB Esophageal Cancer AJCC v7, Stage IIIA Esophageal Cancer AJCC v7, Stage IIIB Esophageal Cancer AJCC v7
- Interventions
- Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment, Radiation Therapy, Therapeutic Conventional Surgery, Trastuzumab
- Drug · Other · Radiation + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 203 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2023
- U.S. locations
- 634
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 407 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 4,740
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma, Refractory Renal Pelvis and Ureter Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v7, Stage IV Renal Pelvis and Ureter Cancer AJCC v7
- Interventions
- Best Practice, Biospecimen Collection, Central Venous Cannula Insertion, Computed Tomography, Enfortumab Vedotin, Magnetic Resonance Imaging, Pembrolizumab, Plasmapheresis, Positron Emission Tomography, Questionnaire Administration, Antibody-Drug Conjugate Therapy
- Other · Procedure · Drug + 1 more
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- HIV Infections, Inpatient Facility Diagnoses
- Interventions
- Team Based Inpatient ARTAS, Standard of Care
- Behavioral
- Lead sponsor
- Loma Linda University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Loma Linda, California
- Conditions
- Sexually Transmitted Diseases
- Interventions
- NgG 12.5 µg investigational vaccine, NgG 25 µg investigational vaccine, NgG 50 µg investigational vaccine, Placebo
- Biological · Combination Product
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 1,009 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 7
- States / cities
- Washington D.C., District of Columbia • Lenexa, Kansas • Boston, Massachusetts + 4 more
- Conditions
- Study Adherence, Depressive Disorder
- Interventions
- Video-Chat Psychotherapy (VCP), Message-Based Psychotherapy (MBP), Message-Based Psychotherapy with Monthly Video-Chat Psychotherapy, Message-Based Psychotherapy with Weekly Video-Chat Psychotherapy, High Monetary Incentive (HMI), Low Monetary and Alternative Incentive (LMAI)
- Behavioral
- Lead sponsor
- Talkspace
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,184 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Healthy Volunteer
- Interventions
- S-648414, Placebo, Midazolam, Dolutegravir
- Drug
- Lead sponsor
- Shionogi
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 98 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Multiple Myeloma
- Interventions
- Melphalan HCl for injection (propylene glycol free)
- Drug
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Breast Neoplasms
- Interventions
- Placebo, Docetaxel, AG-013736 (axitinib)
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 24
- States / cities
- Tucson, Arizona • Berkeley, California • Montebello, California + 17 more
- Conditions
- Osteoarthritis, Knee Osteoarthritis, Arthritis, Joint Diseases, Musculoskeletal Diseases, Rheumatic Diseases
- Interventions
- Exercise for Knee Osteoarthritis Recommendations (Control group), Exercise for Knee Osteoarthritis -(LBPP supported low-load treadmill Walking), Exercise for Knee Osteoarthritis - (Aquatic Walking)
- Other
- Lead sponsor
- Shirley Ryan AbilityLab
- Other
- Eligibility
- 50 Years to 75 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Vaginal Infection
- Interventions
- TOL-463 Vaginal ovule, TOL-463 Vaginal gel
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- HIV-1-infection
- Interventions
- GS-1219, BVY, Standard of Care
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 15
- States / cities
- Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 9 more
- Conditions
- Healthy
- Interventions
- PF-07328948, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- HIV
- Interventions
- Lenacapavir long-acting, Standard of Care (SOC)
- Drug · Other
- Lead sponsor
- Kelley-Ross & Associates, Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Sunscreen
- Interventions
- Sunscreen A, Sunscreen B, Sunscreen C, Sunscreen D, Sunscreen E, Sunscreen F
- Other
- Lead sponsor
- Johnson & Johnson Consumer Inc. (J&JCI)
- Industry
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 97 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Teaneck, New Jersey
- Conditions
- Sexual Behavior
- Interventions
- Healthy Futures, Control
- Behavioral
- Lead sponsor
- JSI Research & Training Institute, Inc.
- Other
- Eligibility
- 10 Years to 15 Years
- Enrollment
- 1,344 participants
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Diabetic Macular Edema
- Interventions
- 0.3 mg ranibizumab, Targeted Pan Retinal Photocoagulation
- Drug · Procedure
- Lead sponsor
- David M. Brown, M.D.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 3
- States / cities
- Houston, Texas • Katy, Texas • The Woodlands, Texas
- Conditions
- COVID-19, Asymptomatic COVID-19
- Interventions
- Proof Lab Test System
- Diagnostic Test
- Lead sponsor
- Proof Diagnostics
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 276 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 3
- States / cities
- Spring Hill, Florida • Statesville, North Carolina • Redmond, Washington
- Conditions
- Atrial Fibrillation
- Interventions
- Rivaroxaban (Xarelto, BAY59-7939), Warfarin sodium
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Whippany, New Jersey
- Conditions
- Information Dissemination, Interprofessional Relations
- Interventions
- Discharge communication software, Usual care discharge process
- Device · Other
- Lead sponsor
- Agency for Healthcare Research and Quality (AHRQ)
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 631 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Peoria, Illinois
- Conditions
- Glycemic Control
- Interventions
- Usual Diet Group, Group 1 Nutritional Shake, Group 2 Nutritional Shake
- Other
- Lead sponsor
- Abbott Nutrition
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 8
- States / cities
- Scottsdale, Arizona • Boca Raton, Florida • Pinellas Park, Florida + 5 more
- Conditions
- Bone Metastases
- Interventions
- Hypofractionated Radiation Treatment, One Radiation Treatment, Questionnaire
- Radiation · Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 167 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 3
- States / cities
- Gilbert, Arizona • Voorhees Township, New Jersey • Houston, Texas
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Leukemia, Myelodysplastic Syndromes, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Myeloproliferative Neoplasm, Lymphoma, Chronic Myelomonocytic Leukemia, Pro-Lymphocytic Leukemia, Myelofibrosis
- Interventions
- Busulfan, Fludarabine, PBSC Hematopoietic Stem Cell Transplantation (HSCT), Post-Transplant Cyclophosphamide, Mesna, Tacrolimus, Mycophenolate Mofetil, Patient Reported Outcomes, Melphalan, Total-body irradiation, Cyclophosphamide
- Drug · Procedure · Other + 1 more
- Lead sponsor
- Center for International Blood and Marrow Transplant Research
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 313 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 32
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 28 more
- Conditions
- Human Immunodeficiency Virus, Chronic Neuropathic Pain
- Interventions
- Low Dose Naltrexone
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia
- Conditions
- Fatigue
- Interventions
- Methylphenidate, Fatigue Evaluations
- Drug · Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2021
- U.S. locations
- 1
- States / cities
- Houston, Texas